Industry News

UnitedHealth Group decided this year to quit selling individual insurance plans on the government-run exchanges, many health policy experts said not to worry. They insisted the move by the nation's biggest health insurer didn't spell doom for the online exchanges that were created as part of President Barack Obama's landmark health care overhaul. But last week, another insurance giant, Aetna, said it was dramatically reducing its 2017 presence on the exchanges,..."/>
A broader look at Missouri's insurance exchange and what Aetna's exit means [St. Louis Post-Dispatch]
Fortis Healthcare Ltd, a Gurgaon-based healthcare company, on Friday said its board of directors had approved the demerger of its diagnostics arm, including the business unit at subsidiary SRL Ltd, into a fully-owned unit Fortis Malar Hospitals Ltd.. The move will separate the company's diagnostic and healthcare businesses and unlock value for shareholders, said Malvinder Singh, executive chairman, Fortis Healthcare. Fortis Healthcare and Fortis Malar are..."/>
Fortis Healthcare board approves demerger of its diagnostics arm [Mint, New Delhi]
Microsoft's efforts to fight cybercrime, counterfeiting and fraud. "It's not just a server room issue."/>
Corporate directors focusing on cybersecurity [The San Diego Union-Tribune]
Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved TROXYCA ® ER extended-release capsules, for oral use, CII for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. TROXYCA ER has properties that are expected to reduce abuse when crushed and administered by the oral and intranasal routes."/>
FDA Approves TROXYCA® ER (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules CII with Abuse-Deterrent Properties for the Management of Pain
M and A Navigator: Deal pipeline –19 August
ViewRay, Inc. announced today that it has entered into a definitive agreement in connection with a private placement of its common stock and warrants that is expected to result in gross proceeds to the Company of approximately $13.75 million. The financing is being led by certain of the Company's existing investors, including OrbiMed Advisors, LLC; Xeraya Capital; and Kearny Venture Partners. It also includes investments from two independent..."/>
ViewRay Announces $13.75 Million Private Placement
SeaSpine Holdings Corp. has entered into a definitive agreement to acquire substantially all of the assets of Israel-based medical device maker NLT Spine Ltd., the company said. NLT Spine develops spinal products for minimally invasive surgery. The company's platforms include vertical, lordotic and footprint expanding interbody technologies for use in lumbar fusion procedures for the treatment of degenerative..."/>
SeaSpine to Acquire Expandable Interbody Platform Technologies
Taro Pharmaceutical Industries Ltd. announced today that it recently completed its $250 million share repurchase program. The company bought back 1,801,099 of its ordinary shares in open market transactions at an average price of $138.80 per share. The repurchase program was announced by the company on March 15, 2016, and was completed on August 18, 2016.."/>
Taro Announces Completion of $250 Million Share Repurchase Program
Amedica Corporation, a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, announced today that on August 17, 2016, the Company received a letter from the Nasdaq Listings Qualifications department of the Nasdaq Capital Market notifying the Company that the minimum bid price per share for its common stock was below $1.00 for a period of thirty consecutive business days and that the Company did not meet the..."/>
Amedica Announces Receipt of Nasdaq Notice of Bid Price Deficiency
SunLink Health Systems, Inc. today announced that a subsidiary has sold its Chestatee Regional Hospital in Dahlonega, GA for approximately $15,000,000. The company expects to recognize an after tax gain of approximately $7,000,000 on the transaction which closed on August 19, 2016. A portion of the proceeds will be allotted for the payment of debt and the balance will be retained for working capital and general corporate purposes. SunLink Health Systems, Inc. is the..."/>
SunLink Health Systems Subsidiary Sells Chestatee Regional Hospital in Dahlonega, Georgia
Covalon Technologies Ltd., an advanced medical technologies company, today announced financial results for its third quarter ended June 30, 2016.. Revenue for the three months ended June 30, 2016 was $2,600,002, operating expenses were $1,793,108 and net loss was $156,793 or $0.02 per share. For the nine months ended June 30, 2016, revenue was $5,838,384, operating expenses were $4594,223 and net loss was $956,087 or $0.07 per share."/>
Covalon Announces Third Quarter Financial Results
WellCare Health Plans, Inc. today announced that the WellCare Community Foundation is donating $10,000 to the American Red Cross to support flood relief efforts in Louisiana. WellCare will also match employee contributions to the Red Cross up to $5,000.. In addition, WellCare has extended the hours of its Community Assistance Line to help connect those impacted with needed social services."/>
WellCare Gives $10,000 to the American Red Cross to Support Flood Relief Efforts in Louisiana
NuVasive faced a critical transition in the spring of 2015, when Alex Lukianov, its charismatic chief executive and founder, resigned over a violation of corporate reimbursement and personnel policies. Lukianov had propelled a wave of innovation into spine surgery, a notoriously difficult field historically plagued with poor results. With instruments and training from the San Diego company, doctors learned to apply minimally invasive..."/>
San Diego's NuVasive rebounds under new leadership [The San Diego Union-Tribune]
BriaCell Therapeutics Corp. is pleased to announce it has completed its previously announced non-brokered private placement financing of units for aggregate gross proceeds to the Company in the amount of $1,700,000.. Under the Offering, each Unit shall consist of one common share in the capital of the Company and one Common Share purchase warrant. The Warrants will be valid for 36 months following the date of..."/>
BriaCell Closes Oversubscribed Non-Brokered Private Placement
Array BioPharma Inc. today announced that results from a Phase 2 study of ARRY-797 will be presented at the 2016 European Society of Cardiology Congress, which will be held August 27– 31, 2016 in Rome, Italy. Updated and additional data will be provided at the conference beyond what is included in the abstract.. All abstracts can be accessed through the ESC website, or on this web page: http://spo.escardio.org/default. aspx?"/>
Array BioPharma Announces Clinical Data Presentation On ARRY-797 At The 2016 European Society Of Cardiology Congress

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary625 Articles
Information Technology579 Articles
Financials474 Articles
Health Care334 Articles
Industrials311 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.